glutathione iv kidney failure 🥇 Therapy in Los Angeles Targeting ferroptosis for treating kidney

10.1007/BF00174084 44 DixonS

doi:10.1056/nejmoa053783 78

[DOI] [PMC free article] [PubMed] [Google Scholar] 65.Li H., Ning S., Ghandi M., Kryukov G.V., Gopal S., Deik A., Souza A., Pierce K., Keskula P., Hernandez D., et al

rxlist.com Austedo Keywords Valbenazine Trade Name: Ingrezza Drug Class: Rx of Tardive dyskinesia (monoamine depletor) Mechanism of Action: a selective competitive inhibitor of VMAT2, similar to tetrabenazine the monoamine vesicular monoamine uptake transporter (VMAT2) transports (loads) cytoplasmic monoamine neurotransmitters (dopamine, norepinephrine, histamine, serotonin) into presynaptic storage vesicles found in sympathetic nerve terminals

Notwithstanding their considerable potential, challenges such as achieving therapeutic concentrations in vivo and tissue-specific delivery impede clinical translation

For example, in one trial, two months of 500 mg/day glutathione lozenges led to measurable lightening in the majority of participants